ArticleNeuro-oncology2015
Expression profiles of 151 pediatric low-grade gliomas reveal molecular differences associated with location and histological subtype.
Open access · bronzeAbstract read
In one paragraph
Article in Neuro-oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 1 pooled it
3.5field-weighted citation impact, top 7% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 56 citations in OpenAlex.
- MYB-QKI rearrangements in angiocentric glioma drive tumorigenicity through a tripartite mechanism.Nature genetics · 2016Pooled it
- A POETIC Phase II study of continuous oral everolimus in recurrent, radiographically progressive pediatric low-grade glioma.Pediatric blood & cancer · 2021Trial
- Desmoplastic infantile astrocytoma/ganglioglioma with rare BRAF V600D mutation.Pediatric blood & cancer · 2017Trial
- Multimodal analysis of pediatric pilocytic astrocytomas reveals tumor location-associated cellular and transcriptional heterogeneity.Neuro-oncology · 2025Article
- Transcriptomics-based characterization of the immuno-stromal microenvironment in pediatric low-grade glioma.Oncoimmunology · 2024Article
- Enrichment of oligodendrocyte precursor phenotypes in subsets of low-grade glioneuronal tumours.Brain communications · 2024Article
- Ganglioglioma deep transcriptomics reveals primitive neuroectoderm neural precursor-like population.Acta neuropathologica communications · 2023Article
- Detection and genomic analysis of BRAF fusions in Juvenile Pilocytic Astrocytoma through the combination and integration of multi-omic data.BMC cancer · 2022Article
- The genomic landscape of dysembryoplastic neuroepithelial tumours and a comprehensive analysis of recurrent cases.Neuropathology and applied neurobiology · 2022Article
- A Toolkit for Profiling the Immune Landscape of Pediatric Central Nervous System Malignancies.Frontiers in immunology · 2022Review
- High-Resolution Cartography of the Transcriptome and Methylome Landscapes of Diffuse Gliomas.Cancers · 2021Article
- Outcomes of BRAF V600E Pediatric Gliomas Treated With Targeted BRAF Inhibition.JCO precision oncology · 2020Article
- Mitogenic and progenitor gene programmes in single pilocytic astrocytoma cells.Nature communications · 2019Article
- Classification of Widely and Rarely Expressed Genes with Recurrent Neural Network.Computational and structural biotechnology journal · 2019Article
- Rare Pediatric Invasive Gliofibroma Has BRAFV600E Mutation and Transiently Responds to Targeted Therapy Before Progressive Clonal Evolution.JCO precision oncology · 2019Article
- Desmoplastic Infantile Ganglioglioma/Astrocytoma (DIG/DIA) Are Distinct Entities with Frequent BRAFV600 Mutations.Molecular cancer research : MCR · 2018Article
- Tectal glioma as a distinct diagnostic entity: a comprehensive clinical, imaging, histologic and molecular analysis.Acta neuropathologica communications · 2018Article
- Methylation profiling of paediatric pilocytic astrocytoma reveals variants specifically associated with tumour location and predictive of recurrence.Molecular oncology · 2018Article
- Integrated DNA methylation analysis identifies topographical and tumoral biomarkers in pilocytic astrocytomas.Oncotarget · 2018Article
- Integrating RNA sequencing into neuro-oncology practice.Translational research : the journal of laboratory and clinical medicine · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors at 7 institutions in 3 countries.
Guillaume BergtholdDepartment of Cancer Biology, Dana-Farber Cancer Institute, and Harvard Medical School, Boston, Massachusetts (G.B., P.B., B.R.P., S.E.S., B.T., R.F.-L., C.S., R.S., R.B.); Broad Institute, Cambridge, Massachusetts (G.B., P.B., B.R.P., S.E.S., B.T., R.F.-L., T.G., R.B.); Pediatric Neuro-Oncology Program, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Dana-Farber Cancer Institute and Boston Children's Hospital, and Harvard Medical School, Boston, Massachusetts (P.B., L.C.G., M.W.K.); Liver Cancer Program, Tisch Cancer Institute, Division of Liver Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York (Y.H.); Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts (S.R., S.S., P.Y.W., A.H.L., K.L.L., J.A.C.); Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute, Boston, Massachusetts (S.R., L.R., B.R., C.L.M., K.L.L.); Department of Neurosurgery, Acibadem University Medical Center, Istanbul, Turkey (M.O.); Department of Pathology, Acibadem University Medical Center, Istanbul, Turkey (A.S.); Department of Neurosurgery, Boston Children's Hospital, Boston, Massachusetts (L.C.G.); Departement de Cancerologie de l'enfant et de l'adolescent, Gustave Roussy and Unité Mixte de Recherche 8203 du Centre National de la Recherche Scientifique, Université Paris-Sud, Villejuif, France (J.G.); Department of Pathology, Boston Children's Hospital, Boston, Massachusetts (K.L.L.).
Pratiti BandopadhayayDepartment of Cancer Biology, Dana-Farber Cancer Institute, and Harvard Medical School, Boston, Massachusetts (G.B., P.B., B.R.P., S.E.S., B.T., R.F.-L., C.S., R.S., R.B.); Broad Institute, Cambridge, Massachusetts (G.B., P.B., B.R.P., S.E.S., B.T., R.F.-L., T.G., R.B.); Pediatric Neuro-Oncology Program, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Dana-Farber Cancer Institute and Boston Children's Hospital, and Harvard Medical School, Boston, Massachusetts (P.B., L.C.G., M.W.K.); Liver Cancer Program, Tisch Cancer Institute, Division of Liver Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York (Y.H.); Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts (S.R., S.S., P.Y.W., A.H.L., K.L.L., J.A.C.); Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute, Boston, Massachusetts (S.R., L.R., B.R., C.L.M., K.L.L.); Department of Neurosurgery, Acibadem University Medical Center, Istanbul, Turkey (M.O.); Department of Pathology, Acibadem University Medical Center, Istanbul, Turkey (A.S.); Department of Neurosurgery, Boston Children's Hospital, Boston, Massachusetts (L.C.G.); Departement de Cancerologie de l'enfant et de l'adolescent, Gustave Roussy and Unité Mixte de Recherche 8203 du Centre National de la Recherche Scientifique, Université Paris-Sud, Villejuif, France (J.G.); Department of Pathology, Boston Children's Hospital, Boston, Massachusetts (K.L.L.).
Yujin HoshidaDepartment of Cancer Biology, Dana-Farber Cancer Institute, and Harvard Medical School, Boston, Massachusetts (G.B., P.B., B.R.P., S.E.S., B.T., R.F.-L., C.S., R.S., R.B.); Broad Institute, Cambridge, Massachusetts (G.B., P.B., B.R.P., S.E.S., B.T., R.F.-L., T.G., R.B.); Pediatric Neuro-Oncology Program, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Dana-Farber Cancer Institute and Boston Children's Hospital, and Harvard Medical School, Boston, Massachusetts (P.B., L.C.G., M.W.K.); Liver Cancer Program, Tisch Cancer Institute, Division of Liver Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York (Y.H.); Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts (S.R., S.S., P.Y.W., A.H.L., K.L.L., J.A.C.); Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute, Boston, Massachusetts (S.R., L.R., B.R., C.L.M., K.L.L.); Department of Neurosurgery, Acibadem University Medical Center, Istanbul, Turkey (M.O.); Department of Pathology, Acibadem University Medical Center, Istanbul, Turkey (A.S.); Department of Neurosurgery, Boston Children's Hospital, Boston, Massachusetts (L.C.G.); Departement de Cancerologie de l'enfant et de l'adolescent, Gustave Roussy and Unité Mixte de Recherche 8203 du Centre National de la Recherche Scientifique, Université Paris-Sud, Villejuif, France (J.G.); Department of Pathology, Boston Children's Hospital, Boston, Massachusetts (K.L.L.).
Shakti RamkissoonDepartment of Cancer Biology, Dana-Farber Cancer Institute, and Harvard Medical School, Boston, Massachusetts (G.B., P.B., B.R.P., S.E.S., B.T., R.F.-L., C.S., R.S., R.B.); Broad Institute, Cambridge, Massachusetts (G.B., P.B., B.R.P., S.E.S., B.T., R.F.-L., T.G., R.B.); Pediatric Neuro-Oncology Program, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Dana-Farber Cancer Institute and Boston Children's Hospital, and Harvard Medical School, Boston, Massachusetts (P.B., L.C.G., M.W.K.); Liver Cancer Program, Tisch Cancer Institute, Division of Liver Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York (Y.H.); Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts (S.R., S.S., P.Y.W., A.H.L., K.L.L., J.A.C.); Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute, Boston, Massachusetts (S.R., L.R., B.R., C.L.M., K.L.L.); Department of Neurosurgery, Acibadem University Medical Center, Istanbul, Turkey (M.O.); Department of Pathology, Acibadem University Medical Center, Istanbul, Turkey (A.S.); Department of Neurosurgery, Boston Children's Hospital, Boston, Massachusetts (L.C.G.); Departement de Cancerologie de l'enfant et de l'adolescent, Gustave Roussy and Unité Mixte de Recherche 8203 du Centre National de la Recherche Scientifique, Université Paris-Sud, Villejuif, France (J.G.); Department of Pathology, Boston Children's Hospital, Boston, Massachusetts (K.L.L.).
Lori RamkissoonDepartment of Cancer Biology, Dana-Farber Cancer Institute, and Harvard Medical School, Boston, Massachusetts (G.B., P.B., B.R.P., S.E.S., B.T., R.F.-L., C.S., R.S., R.B.); Broad Institute, Cambridge, Massachusetts (G.B., P.B., B.R.P., S.E.S., B.T., R.F.-L., T.G., R.B.); Pediatric Neuro-Oncology Program, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Dana-Farber Cancer Institute and Boston Children's Hospital, and Harvard Medical School, Boston, Massachusetts (P.B., L.C.G., M.W.K.); Liver Cancer Program, Tisch Cancer Institute, Division of Liver Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York (Y.H.); Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts (S.R., S.S., P.Y.W., A.H.L., K.L.L., J.A.C.); Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute, Boston, Massachusetts (S.R., L.R., B.R., C.L.M., K.L.L.); Department of Neurosurgery, Acibadem University Medical Center, Istanbul, Turkey (M.O.); Department of Pathology, Acibadem University Medical Center, Istanbul, Turkey (A.S.); Department of Neurosurgery, Boston Children's Hospital, Boston, Massachusetts (L.C.G.); Departement de Cancerologie de l'enfant et de l'adolescent, Gustave Roussy and Unité Mixte de Recherche 8203 du Centre National de la Recherche Scientifique, Université Paris-Sud, Villejuif, France (J.G.); Department of Pathology, Boston Children's Hospital, Boston, Massachusetts (K.L.L.).
Benjamin RichDepartment of Cancer Biology, Dana-Farber Cancer Institute, and Harvard Medical School, Boston, Massachusetts (G.B., P.B., B.R.P., S.E.S., B.T., R.F.-L., C.S., R.S., R.B.); Broad Institute, Cambridge, Massachusetts (G.B., P.B., B.R.P., S.E.S., B.T., R.F.-L., T.G., R.B.); Pediatric Neuro-Oncology Program, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Dana-Farber Cancer Institute and Boston Children's Hospital, and Harvard Medical School, Boston, Massachusetts (P.B., L.C.G., M.W.K.); Liver Cancer Program, Tisch Cancer Institute, Division of Liver Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York (Y.H.); Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts (S.R., S.S., P.Y.W., A.H.L., K.L.L., J.A.C.); Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute, Boston, Massachusetts (S.R., L.R., B.R., C.L.M., K.L.L.); Department of Neurosurgery, Acibadem University Medical Center, Istanbul, Turkey (M.O.); Department of Pathology, Acibadem University Medical Center, Istanbul, Turkey (A.S.); Department of Neurosurgery, Boston Children's Hospital, Boston, Massachusetts (L.C.G.); Departement de Cancerologie de l'enfant et de l'adolescent, Gustave Roussy and Unité Mixte de Recherche 8203 du Centre National de la Recherche Scientifique, Université Paris-Sud, Villejuif, France (J.G.); Department of Pathology, Boston Children's Hospital, Boston, Massachusetts (K.L.L.).
Cecile L MaireDepartment of Cancer Biology, Dana-Farber Cancer Institute, and Harvard Medical School, Boston, Massachusetts (G.B., P.B., B.R.P., S.E.S., B.T., R.F.-L., C.S., R.S., R.B.); Broad Institute, Cambridge, Massachusetts (G.B., P.B., B.R.P., S.E.S., B.T., R.F.-L., T.G., R.B.); Pediatric Neuro-Oncology Program, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Dana-Farber Cancer Institute and Boston Children's Hospital, and Harvard Medical School, Boston, Massachusetts (P.B., L.C.G., M.W.K.); Liver Cancer Program, Tisch Cancer Institute, Division of Liver Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York (Y.H.); Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts (S.R., S.S., P.Y.W., A.H.L., K.L.L., J.A.C.); Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute, Boston, Massachusetts (S.R., L.R., B.R., C.L.M., K.L.L.); Department of Neurosurgery, Acibadem University Medical Center, Istanbul, Turkey (M.O.); Department of Pathology, Acibadem University Medical Center, Istanbul, Turkey (A.S.); Department of Neurosurgery, Boston Children's Hospital, Boston, Massachusetts (L.C.G.); Departement de Cancerologie de l'enfant et de l'adolescent, Gustave Roussy and Unité Mixte de Recherche 8203 du Centre National de la Recherche Scientifique, Université Paris-Sud, Villejuif, France (J.G.); Department of Pathology, Boston Children's Hospital, Boston, Massachusetts (K.L.L.).
Brenton R PaolellaDepartment of Cancer Biology, Dana-Farber Cancer Institute, and Harvard Medical School, Boston, Massachusetts (G.B., P.B., B.R.P., S.E.S., B.T., R.F.-L., C.S., R.S., R.B.); Broad Institute, Cambridge, Massachusetts (G.B., P.B., B.R.P., S.E.S., B.T., R.F.-L., T.G., R.B.); Pediatric Neuro-Oncology Program, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Dana-Farber Cancer Institute and Boston Children's Hospital, and Harvard Medical School, Boston, Massachusetts (P.B., L.C.G., M.W.K.); Liver Cancer Program, Tisch Cancer Institute, Division of Liver Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York (Y.H.); Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts (S.R., S.S., P.Y.W., A.H.L., K.L.L., J.A.C.); Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute, Boston, Massachusetts (S.R., L.R., B.R., C.L.M., K.L.L.); Department of Neurosurgery, Acibadem University Medical Center, Istanbul, Turkey (M.O.); Department of Pathology, Acibadem University Medical Center, Istanbul, Turkey (A.S.); Department of Neurosurgery, Boston Children's Hospital, Boston, Massachusetts (L.C.G.); Departement de Cancerologie de l'enfant et de l'adolescent, Gustave Roussy and Unité Mixte de Recherche 8203 du Centre National de la Recherche Scientifique, Université Paris-Sud, Villejuif, France (J.G.); Department of Pathology, Boston Children's Hospital, Boston, Massachusetts (K.L.L.).
Steven E SchumacherDepartment of Cancer Biology, Dana-Farber Cancer Institute, and Harvard Medical School, Boston, Massachusetts (G.B., P.B., B.R.P., S.E.S., B.T., R.F.-L., C.S., R.S., R.B.); Broad Institute, Cambridge, Massachusetts (G.B., P.B., B.R.P., S.E.S., B.T., R.F.-L., T.G., R.B.); Pediatric Neuro-Oncology Program, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Dana-Farber Cancer Institute and Boston Children's Hospital, and Harvard Medical School, Boston, Massachusetts (P.B., L.C.G., M.W.K.); Liver Cancer Program, Tisch Cancer Institute, Division of Liver Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York (Y.H.); Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts (S.R., S.S., P.Y.W., A.H.L., K.L.L., J.A.C.); Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute, Boston, Massachusetts (S.R., L.R., B.R., C.L.M., K.L.L.); Department of Neurosurgery, Acibadem University Medical Center, Istanbul, Turkey (M.O.); Department of Pathology, Acibadem University Medical Center, Istanbul, Turkey (A.S.); Department of Neurosurgery, Boston Children's Hospital, Boston, Massachusetts (L.C.G.); Departement de Cancerologie de l'enfant et de l'adolescent, Gustave Roussy and Unité Mixte de Recherche 8203 du Centre National de la Recherche Scientifique, Université Paris-Sud, Villejuif, France (J.G.); Department of Pathology, Boston Children's Hospital, Boston, Massachusetts (K.L.L.).
Barbara TabakDepartment of Cancer Biology, Dana-Farber Cancer Institute, and Harvard Medical School, Boston, Massachusetts (G.B., P.B., B.R.P., S.E.S., B.T., R.F.-L., C.S., R.S., R.B.); Broad Institute, Cambridge, Massachusetts (G.B., P.B., B.R.P., S.E.S., B.T., R.F.-L., T.G., R.B.); Pediatric Neuro-Oncology Program, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Dana-Farber Cancer Institute and Boston Children's Hospital, and Harvard Medical School, Boston, Massachusetts (P.B., L.C.G., M.W.K.); Liver Cancer Program, Tisch Cancer Institute, Division of Liver Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York (Y.H.); Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts (S.R., S.S., P.Y.W., A.H.L., K.L.L., J.A.C.); Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute, Boston, Massachusetts (S.R., L.R., B.R., C.L.M., K.L.L.); Department of Neurosurgery, Acibadem University Medical Center, Istanbul, Turkey (M.O.); Department of Pathology, Acibadem University Medical Center, Istanbul, Turkey (A.S.); Department of Neurosurgery, Boston Children's Hospital, Boston, Massachusetts (L.C.G.); Departement de Cancerologie de l'enfant et de l'adolescent, Gustave Roussy and Unité Mixte de Recherche 8203 du Centre National de la Recherche Scientifique, Université Paris-Sud, Villejuif, France (J.G.); Department of Pathology, Boston Children's Hospital, Boston, Massachusetts (K.L.L.).
Ruben Ferrer-LunaDepartment of Cancer Biology, Dana-Farber Cancer Institute, and Harvard Medical School, Boston, Massachusetts (G.B., P.B., B.R.P., S.E.S., B.T., R.F.-L., C.S., R.S., R.B.); Broad Institute, Cambridge, Massachusetts (G.B., P.B., B.R.P., S.E.S., B.T., R.F.-L., T.G., R.B.); Pediatric Neuro-Oncology Program, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Dana-Farber Cancer Institute and Boston Children's Hospital, and Harvard Medical School, Boston, Massachusetts (P.B., L.C.G., M.W.K.); Liver Cancer Program, Tisch Cancer Institute, Division of Liver Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York (Y.H.); Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts (S.R., S.S., P.Y.W., A.H.L., K.L.L., J.A.C.); Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute, Boston, Massachusetts (S.R., L.R., B.R., C.L.M., K.L.L.); Department of Neurosurgery, Acibadem University Medical Center, Istanbul, Turkey (M.O.); Department of Pathology, Acibadem University Medical Center, Istanbul, Turkey (A.S.); Department of Neurosurgery, Boston Children's Hospital, Boston, Massachusetts (L.C.G.); Departement de Cancerologie de l'enfant et de l'adolescent, Gustave Roussy and Unité Mixte de Recherche 8203 du Centre National de la Recherche Scientifique, Université Paris-Sud, Villejuif, France (J.G.); Department of Pathology, Boston Children's Hospital, Boston, Massachusetts (K.L.L.).
Memet OzekDepartment of Cancer Biology, Dana-Farber Cancer Institute, and Harvard Medical School, Boston, Massachusetts (G.B., P.B., B.R.P., S.E.S., B.T., R.F.-L., C.S., R.S., R.B.); Broad Institute, Cambridge, Massachusetts (G.B., P.B., B.R.P., S.E.S., B.T., R.F.-L., T.G., R.B.); Pediatric Neuro-Oncology Program, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Dana-Farber Cancer Institute and Boston Children's Hospital, and Harvard Medical School, Boston, Massachusetts (P.B., L.C.G., M.W.K.); Liver Cancer Program, Tisch Cancer Institute, Division of Liver Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York (Y.H.); Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts (S.R., S.S., P.Y.W., A.H.L., K.L.L., J.A.C.); Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute, Boston, Massachusetts (S.R., L.R., B.R., C.L.M., K.L.L.); Department of Neurosurgery, Acibadem University Medical Center, Istanbul, Turkey (M.O.); Department of Pathology, Acibadem University Medical Center, Istanbul, Turkey (A.S.); Department of Neurosurgery, Boston Children's Hospital, Boston, Massachusetts (L.C.G.); Departement de Cancerologie de l'enfant et de l'adolescent, Gustave Roussy and Unité Mixte de Recherche 8203 du Centre National de la Recherche Scientifique, Université Paris-Sud, Villejuif, France (J.G.); Department of Pathology, Boston Children's Hospital, Boston, Massachusetts (K.L.L.).
Aydin SavDepartment of Cancer Biology, Dana-Farber Cancer Institute, and Harvard Medical School, Boston, Massachusetts (G.B., P.B., B.R.P., S.E.S., B.T., R.F.-L., C.S., R.S., R.B.); Broad Institute, Cambridge, Massachusetts (G.B., P.B., B.R.P., S.E.S., B.T., R.F.-L., T.G., R.B.); Pediatric Neuro-Oncology Program, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Dana-Farber Cancer Institute and Boston Children's Hospital, and Harvard Medical School, Boston, Massachusetts (P.B., L.C.G., M.W.K.); Liver Cancer Program, Tisch Cancer Institute, Division of Liver Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York (Y.H.); Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts (S.R., S.S., P.Y.W., A.H.L., K.L.L., J.A.C.); Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute, Boston, Massachusetts (S.R., L.R., B.R., C.L.M., K.L.L.); Department of Neurosurgery, Acibadem University Medical Center, Istanbul, Turkey (M.O.); Department of Pathology, Acibadem University Medical Center, Istanbul, Turkey (A.S.); Department of Neurosurgery, Boston Children's Hospital, Boston, Massachusetts (L.C.G.); Departement de Cancerologie de l'enfant et de l'adolescent, Gustave Roussy and Unité Mixte de Recherche 8203 du Centre National de la Recherche Scientifique, Université Paris-Sud, Villejuif, France (J.G.); Department of Pathology, Boston Children's Hospital, Boston, Massachusetts (K.L.L.).
Sandro SantagataDepartment of Cancer Biology, Dana-Farber Cancer Institute, and Harvard Medical School, Boston, Massachusetts (G.B., P.B., B.R.P., S.E.S., B.T., R.F.-L., C.S., R.S., R.B.); Broad Institute, Cambridge, Massachusetts (G.B., P.B., B.R.P., S.E.S., B.T., R.F.-L., T.G., R.B.); Pediatric Neuro-Oncology Program, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Dana-Farber Cancer Institute and Boston Children's Hospital, and Harvard Medical School, Boston, Massachusetts (P.B., L.C.G., M.W.K.); Liver Cancer Program, Tisch Cancer Institute, Division of Liver Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York (Y.H.); Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts (S.R., S.S., P.Y.W., A.H.L., K.L.L., J.A.C.); Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute, Boston, Massachusetts (S.R., L.R., B.R., C.L.M., K.L.L.); Department of Neurosurgery, Acibadem University Medical Center, Istanbul, Turkey (M.O.); Department of Pathology, Acibadem University Medical Center, Istanbul, Turkey (A.S.); Department of Neurosurgery, Boston Children's Hospital, Boston, Massachusetts (L.C.G.); Departement de Cancerologie de l'enfant et de l'adolescent, Gustave Roussy and Unité Mixte de Recherche 8203 du Centre National de la Recherche Scientifique, Université Paris-Sud, Villejuif, France (J.G.); Department of Pathology, Boston Children's Hospital, Boston, Massachusetts (K.L.L.).
Patrick Yung WenDepartment of Cancer Biology, Dana-Farber Cancer Institute, and Harvard Medical School, Boston, Massachusetts (G.B., P.B., B.R.P., S.E.S., B.T., R.F.-L., C.S., R.S., R.B.); Broad Institute, Cambridge, Massachusetts (G.B., P.B., B.R.P., S.E.S., B.T., R.F.-L., T.G., R.B.); Pediatric Neuro-Oncology Program, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Dana-Farber Cancer Institute and Boston Children's Hospital, and Harvard Medical School, Boston, Massachusetts (P.B., L.C.G., M.W.K.); Liver Cancer Program, Tisch Cancer Institute, Division of Liver Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York (Y.H.); Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts (S.R., S.S., P.Y.W., A.H.L., K.L.L., J.A.C.); Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute, Boston, Massachusetts (S.R., L.R., B.R., C.L.M., K.L.L.); Department of Neurosurgery, Acibadem University Medical Center, Istanbul, Turkey (M.O.); Department of Pathology, Acibadem University Medical Center, Istanbul, Turkey (A.S.); Department of Neurosurgery, Boston Children's Hospital, Boston, Massachusetts (L.C.G.); Departement de Cancerologie de l'enfant et de l'adolescent, Gustave Roussy and Unité Mixte de Recherche 8203 du Centre National de la Recherche Scientifique, Université Paris-Sud, Villejuif, France (J.G.); Department of Pathology, Boston Children's Hospital, Boston, Massachusetts (K.L.L.).
Liliana C GoumnerovaDepartment of Cancer Biology, Dana-Farber Cancer Institute, and Harvard Medical School, Boston, Massachusetts (G.B., P.B., B.R.P., S.E.S., B.T., R.F.-L., C.S., R.S., R.B.); Broad Institute, Cambridge, Massachusetts (G.B., P.B., B.R.P., S.E.S., B.T., R.F.-L., T.G., R.B.); Pediatric Neuro-Oncology Program, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Dana-Farber Cancer Institute and Boston Children's Hospital, and Harvard Medical School, Boston, Massachusetts (P.B., L.C.G., M.W.K.); Liver Cancer Program, Tisch Cancer Institute, Division of Liver Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York (Y.H.); Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts (S.R., S.S., P.Y.W., A.H.L., K.L.L., J.A.C.); Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute, Boston, Massachusetts (S.R., L.R., B.R., C.L.M., K.L.L.); Department of Neurosurgery, Acibadem University Medical Center, Istanbul, Turkey (M.O.); Department of Pathology, Acibadem University Medical Center, Istanbul, Turkey (A.S.); Department of Neurosurgery, Boston Children's Hospital, Boston, Massachusetts (L.C.G.); Departement de Cancerologie de l'enfant et de l'adolescent, Gustave Roussy and Unité Mixte de Recherche 8203 du Centre National de la Recherche Scientifique, Université Paris-Sud, Villejuif, France (J.G.); Department of Pathology, Boston Children's Hospital, Boston, Massachusetts (K.L.L.).
Azra H LigonDepartment of Cancer Biology, Dana-Farber Cancer Institute, and Harvard Medical School, Boston, Massachusetts (G.B., P.B., B.R.P., S.E.S., B.T., R.F.-L., C.S., R.S., R.B.); Broad Institute, Cambridge, Massachusetts (G.B., P.B., B.R.P., S.E.S., B.T., R.F.-L., T.G., R.B.); Pediatric Neuro-Oncology Program, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Dana-Farber Cancer Institute and Boston Children's Hospital, and Harvard Medical School, Boston, Massachusetts (P.B., L.C.G., M.W.K.); Liver Cancer Program, Tisch Cancer Institute, Division of Liver Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York (Y.H.); Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts (S.R., S.S., P.Y.W., A.H.L., K.L.L., J.A.C.); Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute, Boston, Massachusetts (S.R., L.R., B.R., C.L.M., K.L.L.); Department of Neurosurgery, Acibadem University Medical Center, Istanbul, Turkey (M.O.); Department of Pathology, Acibadem University Medical Center, Istanbul, Turkey (A.S.); Department of Neurosurgery, Boston Children's Hospital, Boston, Massachusetts (L.C.G.); Departement de Cancerologie de l'enfant et de l'adolescent, Gustave Roussy and Unité Mixte de Recherche 8203 du Centre National de la Recherche Scientifique, Université Paris-Sud, Villejuif, France (J.G.); Department of Pathology, Boston Children's Hospital, Boston, Massachusetts (K.L.L.).
Charles StilesDepartment of Cancer Biology, Dana-Farber Cancer Institute, and Harvard Medical School, Boston, Massachusetts (G.B., P.B., B.R.P., S.E.S., B.T., R.F.-L., C.S., R.S., R.B.); Broad Institute, Cambridge, Massachusetts (G.B., P.B., B.R.P., S.E.S., B.T., R.F.-L., T.G., R.B.); Pediatric Neuro-Oncology Program, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Dana-Farber Cancer Institute and Boston Children's Hospital, and Harvard Medical School, Boston, Massachusetts (P.B., L.C.G., M.W.K.); Liver Cancer Program, Tisch Cancer Institute, Division of Liver Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York (Y.H.); Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts (S.R., S.S., P.Y.W., A.H.L., K.L.L., J.A.C.); Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute, Boston, Massachusetts (S.R., L.R., B.R., C.L.M., K.L.L.); Department of Neurosurgery, Acibadem University Medical Center, Istanbul, Turkey (M.O.); Department of Pathology, Acibadem University Medical Center, Istanbul, Turkey (A.S.); Department of Neurosurgery, Boston Children's Hospital, Boston, Massachusetts (L.C.G.); Departement de Cancerologie de l'enfant et de l'adolescent, Gustave Roussy and Unité Mixte de Recherche 8203 du Centre National de la Recherche Scientifique, Université Paris-Sud, Villejuif, France (J.G.); Department of Pathology, Boston Children's Hospital, Boston, Massachusetts (K.L.L.).
Rosalind SegalDepartment of Cancer Biology, Dana-Farber Cancer Institute, and Harvard Medical School, Boston, Massachusetts (G.B., P.B., B.R.P., S.E.S., B.T., R.F.-L., C.S., R.S., R.B.); Broad Institute, Cambridge, Massachusetts (G.B., P.B., B.R.P., S.E.S., B.T., R.F.-L., T.G., R.B.); Pediatric Neuro-Oncology Program, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Dana-Farber Cancer Institute and Boston Children's Hospital, and Harvard Medical School, Boston, Massachusetts (P.B., L.C.G., M.W.K.); Liver Cancer Program, Tisch Cancer Institute, Division of Liver Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York (Y.H.); Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts (S.R., S.S., P.Y.W., A.H.L., K.L.L., J.A.C.); Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute, Boston, Massachusetts (S.R., L.R., B.R., C.L.M., K.L.L.); Department of Neurosurgery, Acibadem University Medical Center, Istanbul, Turkey (M.O.); Department of Pathology, Acibadem University Medical Center, Istanbul, Turkey (A.S.); Department of Neurosurgery, Boston Children's Hospital, Boston, Massachusetts (L.C.G.); Departement de Cancerologie de l'enfant et de l'adolescent, Gustave Roussy and Unité Mixte de Recherche 8203 du Centre National de la Recherche Scientifique, Université Paris-Sud, Villejuif, France (J.G.); Department of Pathology, Boston Children's Hospital, Boston, Massachusetts (K.L.L.).
Todd GolubDepartment of Cancer Biology, Dana-Farber Cancer Institute, and Harvard Medical School, Boston, Massachusetts (G.B., P.B., B.R.P., S.E.S., B.T., R.F.-L., C.S., R.S., R.B.); Broad Institute, Cambridge, Massachusetts (G.B., P.B., B.R.P., S.E.S., B.T., R.F.-L., T.G., R.B.); Pediatric Neuro-Oncology Program, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Dana-Farber Cancer Institute and Boston Children's Hospital, and Harvard Medical School, Boston, Massachusetts (P.B., L.C.G., M.W.K.); Liver Cancer Program, Tisch Cancer Institute, Division of Liver Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York (Y.H.); Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts (S.R., S.S., P.Y.W., A.H.L., K.L.L., J.A.C.); Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute, Boston, Massachusetts (S.R., L.R., B.R., C.L.M., K.L.L.); Department of Neurosurgery, Acibadem University Medical Center, Istanbul, Turkey (M.O.); Department of Pathology, Acibadem University Medical Center, Istanbul, Turkey (A.S.); Department of Neurosurgery, Boston Children's Hospital, Boston, Massachusetts (L.C.G.); Departement de Cancerologie de l'enfant et de l'adolescent, Gustave Roussy and Unité Mixte de Recherche 8203 du Centre National de la Recherche Scientifique, Université Paris-Sud, Villejuif, France (J.G.); Department of Pathology, Boston Children's Hospital, Boston, Massachusetts (K.L.L.).
Jacques GrillDepartment of Cancer Biology, Dana-Farber Cancer Institute, and Harvard Medical School, Boston, Massachusetts (G.B., P.B., B.R.P., S.E.S., B.T., R.F.-L., C.S., R.S., R.B.); Broad Institute, Cambridge, Massachusetts (G.B., P.B., B.R.P., S.E.S., B.T., R.F.-L., T.G., R.B.); Pediatric Neuro-Oncology Program, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Dana-Farber Cancer Institute and Boston Children's Hospital, and Harvard Medical School, Boston, Massachusetts (P.B., L.C.G., M.W.K.); Liver Cancer Program, Tisch Cancer Institute, Division of Liver Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York (Y.H.); Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts (S.R., S.S., P.Y.W., A.H.L., K.L.L., J.A.C.); Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute, Boston, Massachusetts (S.R., L.R., B.R., C.L.M., K.L.L.); Department of Neurosurgery, Acibadem University Medical Center, Istanbul, Turkey (M.O.); Department of Pathology, Acibadem University Medical Center, Istanbul, Turkey (A.S.); Department of Neurosurgery, Boston Children's Hospital, Boston, Massachusetts (L.C.G.); Departement de Cancerologie de l'enfant et de l'adolescent, Gustave Roussy and Unité Mixte de Recherche 8203 du Centre National de la Recherche Scientifique, Université Paris-Sud, Villejuif, France (J.G.); Department of Pathology, Boston Children's Hospital, Boston, Massachusetts (K.L.L.).
Keith L LigonDepartment of Cancer Biology, Dana-Farber Cancer Institute, and Harvard Medical School, Boston, Massachusetts (G.B., P.B., B.R.P., S.E.S., B.T., R.F.-L., C.S., R.S., R.B.); Broad Institute, Cambridge, Massachusetts (G.B., P.B., B.R.P., S.E.S., B.T., R.F.-L., T.G., R.B.); Pediatric Neuro-Oncology Program, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Dana-Farber Cancer Institute and Boston Children's Hospital, and Harvard Medical School, Boston, Massachusetts (P.B., L.C.G., M.W.K.); Liver Cancer Program, Tisch Cancer Institute, Division of Liver Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York (Y.H.); Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts (S.R., S.S., P.Y.W., A.H.L., K.L.L., J.A.C.); Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute, Boston, Massachusetts (S.R., L.R., B.R., C.L.M., K.L.L.); Department of Neurosurgery, Acibadem University Medical Center, Istanbul, Turkey (M.O.); Department of Pathology, Acibadem University Medical Center, Istanbul, Turkey (A.S.); Department of Neurosurgery, Boston Children's Hospital, Boston, Massachusetts (L.C.G.); Departement de Cancerologie de l'enfant et de l'adolescent, Gustave Roussy and Unité Mixte de Recherche 8203 du Centre National de la Recherche Scientifique, Université Paris-Sud, Villejuif, France (J.G.); Department of Pathology, Boston Children's Hospital, Boston, Massachusetts (K.L.L.).
Jennifer A ChanDepartment of Cancer Biology, Dana-Farber Cancer Institute, and Harvard Medical School, Boston, Massachusetts (G.B., P.B., B.R.P., S.E.S., B.T., R.F.-L., C.S., R.S., R.B.); Broad Institute, Cambridge, Massachusetts (G.B., P.B., B.R.P., S.E.S., B.T., R.F.-L., T.G., R.B.); Pediatric Neuro-Oncology Program, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Dana-Farber Cancer Institute and Boston Children's Hospital, and Harvard Medical School, Boston, Massachusetts (P.B., L.C.G., M.W.K.); Liver Cancer Program, Tisch Cancer Institute, Division of Liver Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York (Y.H.); Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts (S.R., S.S., P.Y.W., A.H.L., K.L.L., J.A.C.); Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute, Boston, Massachusetts (S.R., L.R., B.R., C.L.M., K.L.L.); Department of Neurosurgery, Acibadem University Medical Center, Istanbul, Turkey (M.O.); Department of Pathology, Acibadem University Medical Center, Istanbul, Turkey (A.S.); Department of Neurosurgery, Boston Children's Hospital, Boston, Massachusetts (L.C.G.); Departement de Cancerologie de l'enfant et de l'adolescent, Gustave Roussy and Unité Mixte de Recherche 8203 du Centre National de la Recherche Scientifique, Université Paris-Sud, Villejuif, France (J.G.); Department of Pathology, Boston Children's Hospital, Boston, Massachusetts (K.L.L.).
Mark W KieranDepartment of Cancer Biology, Dana-Farber Cancer Institute, and Harvard Medical School, Boston, Massachusetts (G.B., P.B., B.R.P., S.E.S., B.T., R.F.-L., C.S., R.S., R.B.); Broad Institute, Cambridge, Massachusetts (G.B., P.B., B.R.P., S.E.S., B.T., R.F.-L., T.G., R.B.); Pediatric Neuro-Oncology Program, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Dana-Farber Cancer Institute and Boston Children's Hospital, and Harvard Medical School, Boston, Massachusetts (P.B., L.C.G., M.W.K.); Liver Cancer Program, Tisch Cancer Institute, Division of Liver Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York (Y.H.); Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts (S.R., S.S., P.Y.W., A.H.L., K.L.L., J.A.C.); Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute, Boston, Massachusetts (S.R., L.R., B.R., C.L.M., K.L.L.); Department of Neurosurgery, Acibadem University Medical Center, Istanbul, Turkey (M.O.); Department of Pathology, Acibadem University Medical Center, Istanbul, Turkey (A.S.); Department of Neurosurgery, Boston Children's Hospital, Boston, Massachusetts (L.C.G.); Departement de Cancerologie de l'enfant et de l'adolescent, Gustave Roussy and Unité Mixte de Recherche 8203 du Centre National de la Recherche Scientifique, Université Paris-Sud, Villejuif, France (J.G.); Department of Pathology, Boston Children's Hospital, Boston, Massachusetts (K.L.L.).
Rameen BeroukhimDepartment of Cancer Biology, Dana-Farber Cancer Institute, and Harvard Medical School, Boston, Massachusetts (G.B., P.B., B.R.P., S.E.S., B.T., R.F.-L., C.S., R.S., R.B.); Broad Institute, Cambridge, Massachusetts (G.B., P.B., B.R.P., S.E.S., B.T., R.F.-L., T.G., R.B.); Pediatric Neuro-Oncology Program, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Dana-Farber Cancer Institute and Boston Children's Hospital, and Harvard Medical School, Boston, Massachusetts (P.B., L.C.G., M.W.K.); Liver Cancer Program, Tisch Cancer Institute, Division of Liver Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York (Y.H.); Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts (S.R., S.S., P.Y.W., A.H.L., K.L.L., J.A.C.); Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute, Boston, Massachusetts (S.R., L.R., B.R., C.L.M., K.L.L.); Department of Neurosurgery, Acibadem University Medical Center, Istanbul, Turkey (M.O.); Department of Pathology, Acibadem University Medical Center, Istanbul, Turkey (A.S.); Department of Neurosurgery, Boston Children's Hospital, Boston, Massachusetts (L.C.G.); Departement de Cancerologie de l'enfant et de l'adolescent, Gustave Roussy and Unité Mixte de Recherche 8203 du Centre National de la Recherche Scientifique, Université Paris-Sud, Villejuif, France (J.G.); Department of Pathology, Boston Children's Hospital, Boston, Massachusetts (K.L.L.).
Dana-Farber Cancer Institute · USHarvard University Press · USAcıbadem Adana Hospital · TRHarvard University · USBroad Institute · USIcahn School of Medicine at Mount Sinai · USUniversity Medical Center · US
Funding
Targeting the Vasular SystemP50CA165962 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI DAPHNE A. HAAS-KOGAN · 2013 to 2026
$33.5MTherapeutic Opportunities for Pediatric AstrocytomaP01CA142536 · NCI · DANA-FARBER CANCER INST · PI HAHN, WILLIAM C. · 2011 to 2015
$7.9MMolecular Prognostic Indicators in Liver Cirrhosis and CancerR01DK099558 · NIDDK · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI HOSHIDA, YUJIN · 2013 to 2016
$2.6MALK signaling in CNS development, ischemic brain injury and gliomagenesisK08NS087118 · NINDS · BRIGHAM AND WOMEN'S HOSPITAL · PI RAMKISSOON, SHAKTI H · 2014 to 2015
$387kCancer Specific Sensitivity to Suppression of Spliceosome ComponentsF32CA180653 · NCI · DANA-FARBER CANCER INST · PI PAOLELLA, BRENTON ROBERT · 2014 to 2017
$148kNCI NIH HHS F32 CA180653NCI NIH HHS P01 CA142536NCI NIH HHS P01CA142536NCI NIH HHS P50 CA165962NIDDK NIH HHS R01 DK099558NINDS NIH HHS K08 NS087118
Abstract
backgroundPediatric low-grade gliomas (PLGGs), the most frequent pediatric brain tumor, comprise a heterogeneous group of diseases. Recent genomic analyses suggest that these tumors are mostly driven by mitogene-activated protein kinase (MAPK) pathway alterations. However, little is known about the molecular characteristics inherent to their clinical and histological heterogeneity.
methodsWe performed gene expression profiling on 151 paraffin-embedded PLGGs from different locations, ages, and histologies. Using unsupervised and supervised analyses, we compared molecular features with age, location, histology, and BRAF genomic status. We compared molecular differences with normal pediatric brain expression profiles to observe whether those patterns were mirrored in normal brain.
resultsUnsupervised clustering distinguished 3 molecular groups that correlated with location in the brain and histological subtype. "Not otherwise specified" (NOS) tumors did not constitute a unified class. Supratentorial pilocytic astrocytomas (PAs) were significantly enriched with genes involved in pathways related to inflammatory activity compared with infratentorial tumors. Differences based on tumor location were not mirrored in location-dependent differences in expression within normal brain tissue. We identified significant differences between supratentorial PAs and diffuse astrocytomas as well as between supratentorial PAs and dysembryoplastic neuroepithelial tumors but not between supratentorial PAs and gangliogliomas. Similar expression patterns were observed between childhood and adolescent PAs. We identified differences between BRAF-duplicated and V600E-mutated tumors but not between primary and recurrent PLGGs.
conclusionExpression profiling of PLGGs reveals significant differences associated with tumor location, histology, and BRAF genomic status. Supratentorial PAs, in particular, are enriched in inflammatory pathways that appear to be tumor-related.
Indexed as
TranscriptomeAdolescentBrain NeoplasmsChildChild, PreschoolCluster AnalysisFemaleGene Expression ProfilingGliomaHumansImmunohistochemistryInfantInfant, NewbornIn Situ Hybridization, FluorescenceMaleNeoplasm GradingBRAF duplicationBRAF mutationexpressionheterogeneitypediatric low-grade glioma
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.